Abolere mortem
Research worth understanding. News worth reading. A clearer view of living longer.
New here? Take the guided tour →Important findings, useful explanations, and setbacks worth knowing about.
A quieter news window: showing the latest available stories with their original publication dates. Ranking reflects relevance, recency and reader interest—not proof of benefit.
News, research and the studies that currently shape the longevity chart—all in one stream.
World Health Organization reports on this topic. Open the source for the full explanation.
Source coverage · not an evidence rating
Read the source · World Health Organization ↗74 studies; 2,584,766 participants in the all-cause mortality analysis.
Adults in prospective cohorts; populations and lifestyle definitions varied.
Healthiest versus least-healthy combinations of smoking, activity, diet, weight and alcohol factors.
Observational association, with residual confounding and heterogeneous lifestyle scores. Not the effect of changing an average person’s habits. Alcohol in the score is not a recommendation to drink.
Umbrella review of meta-analyses; equivalent hazard ratio for leisure-time physical activity.
Adults in the self-reported leisure-time physical activity syntheses.
Higher versus lower self-reported leisure-time physical activity; contrasts vary across studies.
Authors classify the association as suggestive evidence. Self-report, residual confounding and overlapping reviews limit interpretation. Replaces the combined lifestyle estimate rather than stacking on it.
CTT individual participant meta-analysis of 26 trials; about 170,000 participants overall.
Participants enrolled in randomized LDL-lowering trials, with varied cardiovascular risk.
Per 1 mmol/L lower LDL cholesterol, across statin versus control and more- versus less-intensive regimens.
Mortality rate ratio is treated as a proportional hazard multiplier in this model. Trial populations and LDL changes differ; not a longevity estimate for healthy people or a prescribing recommendation.
10 randomized trials; 71,351 participants.
People with type 2 diabetes in large cardiovascular and kidney outcome trials.
Long-acting GLP-1 receptor agonist versus placebo, on top of trial background care.
Class-level synthesis in type 2 diabetes; not transferable to healthy adults, every agent, or lifelong use. Trials already include other care, so combining effects can double-count benefit.
Systematic review of 14 randomized trials; all-cause mortality is a secondary endpoint.
People with chronic kidney disease, with or without type 2 diabetes.
SGLT2 inhibitor plus standard therapy versus placebo or standard therapy.
The 14 trials cover the review as a whole, not necessarily this endpoint. Kidney disease populations differ from the reference life table. Background treatment overlaps with other selections.
Explore a topic, read its evidence, and follow future updates.